Hi {{ session.user.profile.firstName }}

Generic Microfluidic Platform for Ultrafast Forensic DNA Analysis

Manage webcast
James Landers, University of Virginia, Professor Chemistry
Generic Microfluidic Platform for Ultrafast Forensic DNA Analysis
Jan 30 2009
49 mins
Generic Microfluidic Platform for Ultrafast Forensic DNA Analysis
More from this community:

Forensic Science

  • Date
  • Rating
  • Views
  • This webinar will focus on operations and maintenance of the StatSpin Express 3 centrifuge. By performing simple inspections, routine maintenance and operating the centrifuges as described in this webinar, you can maximize your StatSpin Express 3 uptime and sustain your productivity.
  • RNAi screening has made it possible to identify new genes, or gene networks, that are involved in a wide vari¬ety of biological processes, including assays relevant to signal transduction, cell viability, cell morphology, protein localization and function, drug resistance, and responses of host cells to pathogens. As such, RNAi continues to help us gain critical insights into the mechanisms underlying human disease and accelerate the development of treatments for cancer and a host of other disorders. The intersection between RNAi screening and complementary approaches such as CRISPR-Cas9-mediated genome editing has opened up new opportunities for assay development, screening and validation. The successful implementation of genome-editing technologies in several species suggests this will serve as an important and relevant tool for validation studies in numerous cell lines and model systems. Additionally, RNAi rescue experiments using LentiORFs serve an important role in further validating and boosting confidence of screened hits. As we continue to develop new strategies to improve genome-wide RNAi screening and validation, the significance of RNAi as a research tool will remain for many years to come.
  • Computer Aided Synthetic Design: How ARChem Can Improve Your Efficiency and Creativity

    Are you looking for a better way to synthesize a target molecule?

    Have you hit a roadblock in the lab or need an extra burst of creative thinking?

    Join Orr Ravitz at 10:00 AM (EDT) on July 16th for an overview of the future of synthetic design and the software that can help improve your efficiency and creativity in the lab with ARChem.

    He will discuss how medicinal chemists, process chemists and material scientists use ARChem as an idea generator – a tool for route scouting, for brain storming sessions, for the daily synthesis planning and potentially provide an alternative that gets you to curated experimental pathways faster than exploring the literature.

    This webinar will cover:

    ◦The technology behind ARChem and real life case studies
    ◦How ARChem can improve your productivity and creativity in the lab
    ◦Future developments of our synthetic design software
  • RNAi screening has made it possible to identify new genes, or gene networks, that are involved in a wide vari¬ety of biological processes, including assays relevant to signal transduction, cell viability, cell morphology, protein localization and function, drug resistance, and responses of host cells to pathogens. As such, RNAi continues to help us gain critical insights into the mechanisms underlying human disease and accelerate the development of treatments for cancer and a host of other disorders. The intersection between RNAi screening and complementary approaches such as CRISPR-Cas9-mediated genome editing has opened up new opportunities for assay development, screening and validation. The successful implementation of genome-editing technologies in several species suggests this will serve as an important and relevant tool for validation studies in numerous cell lines and model systems. Additionally, RNAi rescue experiments using LentiORFs serve an important role in further validating and boosting confidence of screened hits. As we continue to develop new strategies to improve genome-wide RNAi screening and validation, the significance of RNAi as a research tool will remain for many years to come.
  • Understanding your customers is fundamental to effective communication. Current segmentation strategies draw on ever more detailed information about how patients, physicians and payers behave through the use of open source, social media and real world data. However, segmentation still lacks clear insight into why these stakeholders behave as they do – and therefore how best to change their behaviour.
    Working with behavioural change experts Hamell, this one hour live discussion will look at why current segmentation strategies are failing, and the importance of understanding what drives patient or customer behaviour. Using case studies, speakers will explore how segmenting by behavioural drivers can create advanced, effective strategies to change patient, customer and payer behaviour.
    This event will focus on three key areas:

    •The theory behind behavioural segmentation and how it challenges the status quo
    •Benefits of behavioural segmentation communication strategies and the problems answered by behavioural segmentation strategies
    •Behavioural segmentation in action: practical application of this approach
  • Life sciences companies need to make better use of the insights that real world data (RWD) can provide in order to improve market access, sales and market growth strategies – and ultimately to improve the applicability of new and existing therapeutics for patients. Insights come not just from the multiple sources of RWD available, but from advanced analytics that highlight the effectiveness of a treatment by geographic area, and link healthcare providers, institutions and patients to relevant and meaningful outcomes.

    This one-hour event will take a hands-on approach – detailing how insights derived from RWD (and collaboratively with other sources) are enabling all elements of the life science industry to do things better.

    Insights experts Robin Munro and Christian Marcazzo will deliver case studies on how RWD can help life science companies in:

    Sales and Marketing – incorporate RWD and evidence into segmentation, targeting, and engagement of physicians and institutions
    Commercial Effectiveness – measure commercial campaigns, and demonstrate the impact to the healthcare system
    Medical Affairs – find and engage medical education prospects and target appropriate healthcare authorities, healthcare professionals and payers, to improve quality of care and outcomes
    Public Affairs and Market Access – develop qualitative and quantitative insights to design education, advocacy and access-related campaigns within the healthcare ecosystem

    The event will also give an exclusive look at what can be achieved from combining data sources – using Diabetes in England as a case study, Zephyr has implemented novel methods to demonstrate an evidence-based approach to improving information sharing within sales teams and to engaging accounts and payers. We explore how patient outcomes from RWD can add value to commercial strategy.
  • Cell lines remain the workhorses of laboratory research, both in academic and industrial settings. This webinar will focus on best practice in selecting and maintaining cell lines for research, to ensure research outputs are relevant and reproducible. Features of cell lines that might be used in selection will be discussed. This will include monolayer or suspension culture; passage number; doubling time; immortalisation; karyotype; receptors; expression profiling and use of bioinformatics tools like the cancer cell line encyclopaedia. Using breast cancer as an exemplar, I will discuss more specifically how to choose the most relevant cell line model to address a particular research question. Finally I will describe how to use (and access) human material to help develop more clinically relevant cell culture systems to model human disease and the role that biobanks play in this process.
  • Cell lines remain the workhorses of laboratory research, both in academic and industrial settings. This webinar will focus on best practice in selecting and maintaining cell lines for research, to ensure research outputs are relevant and reproducible. Features of cell lines that might be used in selection will be discussed. This will include monolayer or suspension culture; passage number; doubling time; immortalisation; karyotype; receptors; expression profiling and use of bioinformatics tools like the cancer cell line encyclopaedia. Using breast cancer as an exemplar, I will discuss more specifically how to choose the most relevant cell line model to address a particular research question. Finally I will describe how to use (and access) human material to help develop more clinically relevant cell culture systems to model human disease and the role that biobanks play in this process.
  • The way that physicians want and need to consume information is changing, almost to the point of being unrecognisable from the tried and tested methods of yesteryear, Working in conjunction with Ashfield Healthcare this event brings together Medical Futurist Dr Bertalan Meskó, Dr Partha Kar, Consultant Endocrinologist, Portsmouth Hospitals NHS Trust, with Ruth Herman and Nigel Campbell of Ashfield, which recently launched the Medical Education Future Forum and will be presenting insights from this unique programme.

    Taking place on the 21st May at 12.30 (UK), 13.30 (EU), 07.30 (E. US) and moderated by pharmaphorum's CEO Paul Tunnah, the debate will centre on three key questions,

    Why and how are physicians changing the way they receive information?
    What are the trends and technologies shaping the landscape of medical communication?
    What are the implications of this for pharma (with examples)?
  • Improve Your Mass Spectrometry Workflows With the New NIST Software, Featuring the Wiley 10th/NIST 2014

    Hosted by Prof David Sparkman

    Release 2.2 is one of the most significant improvements in NIST’s MS Search software. Prof Sparkman will lead an online webinar providing insight into the latest improvements in the most popular mass spectrometry program on the planet, with insights into how you can improve and speed up your analyses by using the full suite of functions available in MS Search 2.2 and the power of using these with the broadest compound coverage available.
    -Compatibility and systems interface tips
    -Retention time workflow
    -LCMSn workflow
    -Accurate mass workflow
    -Search strategies
    -Compound coverage strategies

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: Generic Microfluidic Platform for Ultrafast Forensic DNA Analysis
  • Live at: Jan 30 2009 9:00 pm
  • Presented by: James Landers, University of Virginia, Professor Chemistry
  • From:
Your email has been sent.
or close
You must be logged in to email this